FDA Approves Adbry (tralokinumab-ldrm) Autoinjector for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis (AD)
MADISON, N.J.--(BUSINESS WIRE)-- June 13, 2024. LEO Pharma Inc. has today announced approval from the U.S. Food and Drug Administration (FDA) for a new Adbry (tralokinumab-ldrm) 300 mg single-dose autoinjector for adult patients. Adbry, a high-affinity fully human monoclonal antibody, is currently indicated in the U.S. for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older.
- Single-dose autoinjector will provide adult patients in the U.S. with an alternative method of administration for Adbry, with the device planned to be available in the coming months.
- The autoinjector device provides a more convenient self-administration option for patients and reduces the number of injections required.
- The FDA approval increases the options available for the estimated 6.6 million adults who live with moderate-to-severe atopic dermatitis (AD) in the U.S.
The new autoinjector will provide another option for adult patients in addition to the pre-filled syringe administration that is currently available. Prior to the introduction of the autoinjector, Adbry was only available in a 1 mL pre-filled syringe. With the new 2 mL autoinjector, adult patients now have a more convenient option with half the number of required injections compared to the 1 mL pre-filled syringe.
“We are constantly looking for new ways to advance the standard of care and improve the patient experience for our treatment options,” said Brian Hilberdink, EVP and President, Region North America, LEO Pharma. “Through this latest approval, a new mode of administration has been made available to provide a more convenient option to support self-administration. Our team will now undertake the necessary steps to ensure patients living across the United States have access to this device in the coming months.”
For patients who prefer the pre-filled syringe, this option will continue to be available in the U.S.
“We understand that no patient is the same, and through this extended approval we have taken a positive step forward to equip those living with AD with more choices,” commented Shannon Schneider, Senior Medical Affairs Director, LEO Pharma. “Alongside the previously approved pre-filled syringe, the autoinjector will give adult patients in the U.S more options than ever before in how they administer their treatment.”
In the U.S., Adbry is available in a single-use pre-filled syringe (150 mg/1 mL) as well as a single-use autoinjector (300 mg/2 mL). Adbry received approval from the U.S. FDA in December 2021 for the treatment of moderate-to-severe atopic dermatitis in adults. Subsequently, in December 2023, the indication was expanded to include pediatric patients 12 years and older. The autoinjector received approval in June 2024 for adult patients.
Adbry (tralokinumab-ldrm) is marketed outside of the U.S. under the tradename Adtralza® (tralokinumab) and is approved for the treatment of adults and pediatric patients (12 years and above) with moderate-to-severe AD in the U.S., Canada, the European Union, the United Arab Emirates, Great Britain, and South Korea. Adtralza is approved for use in adults with moderate-to-severe AD in Saudi Arabia, Switzerland, and Japan.
About atopic dermatitis
Atopic dermatitis is a chronic, inflammatory skin disease characterized by intense itch and eczematous lesions. Atopic dermatitis is the result of skin barrier dysfunction and immune dysregulation, leading to chronic inflammation. Type 2 cytokines, including IL-13, play an important role in the key aspects of atopic dermatitis pathophysiology.
About Adbry (tralokinumab-ldrm)
Adbry (tralokinumab-ldrm), which is marketed outside of the U.S. under the tradename Adtralza (tralokinumab), is a high-affinity fully human monoclonal antibody developed to bind to and inhibit the interleukin (IL)-13 cytokine, which plays a role in the immune and inflammatory processes underlying atopic dermatitis signs and symptoms. Adbry® specifically binds to the IL-13 cytokine, thereby inhibiting interaction with the IL-13 receptor α1 and α2 subunits (IL-13Rα1 and IL-13Rα2).
What is Adbry?
Adbry (tralokinumab-ldrm) injection is a prescription medicine used to treat people 12 years of age and older with moderate-to-severe atopic dermatitis (eczema) that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies. Adbry can be used with or without topical corticosteroids.
It is not known if Adbry is safe and effective in children under 12 years of age.
Do not use Adbry if you are allergic to tralokinumab or to any of its ingredients.
About LEO Pharma
LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, and today, the company offers a wide range of therapies for all disease severities. LEO Pharma is headquartered in Denmark with a global team of 4,200 people, serving millions of patients across the world. In 2023, the company generated net sales of DKK 11.4 billion.
Source: LEO Pharma Inc.
Posted: June 2024
Related articles
- LEO Pharma Inc. Announces U.S. FDA Approval of Adbry (tralokinumab-ldrm) for the Treatment of Moderate-to-Severe Atopic Dermatitis in Pediatric Patients Aged 12-17 Years - December 15, 2023
- FDA Approves Adbry (tralokinumab-ldrm) for Adults with Moderate-to-Severe Atopic Dermatitis - December 28, 2021
Adbry (tralokinumab-ldrm) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.